This ongoing phase III study seeks to further evaluate the therapeutic potential of telisotuzumab vedotin in comparison to docetaxel in NSCLC patients with c-MET overexpression, aiming to solidify its role in the treatment landscape of this challenging malignancy. Here, MET is linked to non-small cell lung carcinoma.